Pinnacle Medicines raised $89 million in a Series B to advance its oral peptide programs, according to deal terms that bring total financing to $134 million. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including Orbimed. In parallel, Wave Life Sciences faced investor pressure after obesity-related readouts suggested limited benefit from higher dosing of its INHBE-targeted approach, with the company’s market capitalization reportedly dropping sharply after Phase I data from WVE-007. Analysts and investors treated the update as evidence that dose escalation may not unlock additional efficacy. Together, the items show contrasting capital dynamics in metabolic medicine—funding for oral peptide pipeline expansion alongside market reassessment for RNA-targeted obesity programs.